<?xml version="1.0" encoding="UTF-8"?>
<p>The observations from the previous SARS epidemic (2003â€“2009) that some coronaviruses use heparan sulfate as a receptor entry by acquiring heparan sulfate-binding sites, and that the heparin molecule acts as competitor preventing the binding of the spike protein to the host cell, inhibiting infection rate and mortality, are a valuable rationale to start heparin treatment in selected COVID-19 patients [
 <xref rid="B59-ijms-21-03474" ref-type="bibr">59</xref>,
 <xref rid="B60-ijms-21-03474" ref-type="bibr">60</xref>,
 <xref rid="B61-ijms-21-03474" ref-type="bibr">61</xref>,
 <xref rid="B62-ijms-21-03474" ref-type="bibr">62</xref>]. This approach might have a double result, to reduce virus entry and avert thrombotic complications or organ dysfunctions [
 <xref rid="B18-ijms-21-03474" ref-type="bibr">18</xref>,
 <xref rid="B21-ijms-21-03474" ref-type="bibr">21</xref>,
 <xref rid="B22-ijms-21-03474" ref-type="bibr">22</xref>].
</p>
